Robert Agee, MD
Family Medicine · Birmingham, ALNPI 1417035270
Payments from drug & device makers
Across 29 payments — averaging $132.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$3K
- Stryker$152
- Metuchen Pharmaceuticals$130
- Dexcom, Inc.$118
- Novo Nordisk$112
- Bioventus LLC$42
- plus $204 from 9 others
What the payments were for
- Speaking & faculty fees$2,76372%
- Food & beverage$1,09028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 9 | $3,095 |
| Stryker | 3 | $152 |
| Metuchen Pharmaceuticals | 1 | $130 |
| Dexcom, Inc. | 1 | $118 |
| Novo Nordisk | 1 | $112 |
| Bioventus LLC | 3 | $42 |
| Kerecis Limited | 2 | $38 |
| Amgen(2 entities) | 2 | $34 |
| Averitas Pharma Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Brainscope Company, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Orexo US, Inc. | 1 | $16 |
| Zimmer Biomet | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilretta$2,885
- Stendra$130
- DEXCOM G7 GSS (161)$118
- Ozempic$112
How this compares
$3,853 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QutenzaCapsaicin/Skin Cleanser | 24 | $78,534 |
| Clobetasol Propionate | 60 | $14,028 |
| Halobetasol Propionate | 35 | $7,927 |
| Desoximetasone | 15 | $6,749 |
| Alclometasone Dipropionate | 30 | $4,591 |
| Etodolac | 77 | $3,408 |
| Fluticasone Propionate | 21 | $2,018 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 143 | $946 |
| Gabapentin | 99 | $802 |
| Methylprednisolone | 90 | $777 |
| Meloxicam | 166 | $740 |
| Methocarbamol | 102 | $655 |
| Celecoxib | 30 | $574 |
| Tizanidine Hcl | 73 | $517 |
| Nabumetone | 16 | $485 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Birmingham
- Michael VaughnBirmingham$9.9M
- Song YuBirmingham$1.7M
- Nova LawBirmingham$649K
- Lashelle BarmoreBirmingham$486K
- Scott WeisbergBirmingham$38K
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.